Evidence map›Paper›PMID 32612145›Full record

ArticleScientific reports2020

mTOR sustains inflammatory response in celiac disease.

S Sedda, V Dinallo, I Marafini, E Franzè, O A Paoluzi, R Izzo, P Giuffrida, A Di Sabatino, G R Corazza, G Monteleone

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. The protective role ofFrontiers in medicine · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

S Sedda *Department of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
V Dinallo *Department of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
I MarafiniDepartment of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
E FranzèDepartment of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
O A PaoluziDepartment of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy.
R IzzoMedpace Spain, Madrid, Spain.
P GiuffridaDipartimento Di Medicina Interna, Fondazione IRCCS Policlinico San Matteo, Università Di Pavia, Pavia, Italy.
A Di SabatinoDipartimento Di Medicina Interna, Fondazione IRCCS Policlinico San Matteo, Università Di Pavia, Pavia, Italy.ORCID http://orcid.org/0000-0002-0302-8645
G R CorazzaDipartimento Di Medicina Interna, Fondazione IRCCS Policlinico San Matteo, Università Di Pavia, Pavia, Italy.
G MonteleoneDepartment of Systems Medicine, University of "Tor Vergata", Via Montpellier, 1, 00133, Rome, Italy. Gi.Monteleone@med.uniroma2.it.
University of Rome Tor Vergata · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Celiac disease (CD) is an enteropathy triggered by the ingestion of gluten proteins in genetically predisposed individuals and characterized by excessive activation of effector immune cells and enhanced production of inflammatory cytokines. However, factors/mechanisms that amplify the ongoing mucosal inflammation in CD are not fully understood. In this study, we assessed whether mammalian target of Rapamycin (mTOR), a pathway that combines intra- and extra-cellular signals and acts as a central regulator for the metabolism, growth, and function of immune and non-immune cells, sustains CD-associated immune response. Our findings indicate that expression of phosphorylated (p)/active form of mTOR is increased in protein lysates of duodenal biopsy samples taken from patients with active CD (ACD) as compared to normal controls. In ACD, activation of mTOR occurs mainly in the epithelial compartment and associates with enhanced expression of p-4EBP, a downstream target of mTOR complex (mTORC)1, while expression of p-Rictor, a component of mTORC2, is not increased. Stimulation of mucosal explants of inactive CD patients with pepsin-trypsin-digested (PT)-gliadin or IFN-γ/IL-21, two cytokines produced in CD by gluten-specific T cells, increases p-4EBP expression. Consistently, blockade of such cytokines in cultures of ACD mucosal explants reduces p-4EBP. Finally, we show that inhibition of mTORC1 with rapamycin in ACD mucosal explants reduces p-4EBP and production of IL-15, a master cytokine produced by epithelial cells in this disorder. Our data suggest that ACD inflammation is marked by activation of mTORC1 in the epithelial compartment.

Indexed as

BiopsyCeliac DiseaseDuodenumFemaleGliadinHumansInflammationInterferon-gammaInterleukin-21InterleukinsIntestinal MucosaMaleMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2PhosphorylationT-LymphocytesGliadinIFNG protein, humanInterferon-gammaInterleukin-21InterleukinsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MTOR protein, humanTOR Serine-Threonine Kinases

Identifiers

PMID32612145
PMCPMC7329835
OpenAlexW3040643851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.